Click Expat Hub to Follow↑
■ Information and Resources for Expats
■Follow for Daily Updates and News
•The Ad5-nCoV vaccine is a recombinant adenovirus vector vaccine jointly developed by CanSino Biologics and researchers from the Institute of Military Medicine under the Academy of Military Sciences
•"We have data for six months so far to prove the vaccine's efficacy People don't need to take another dose within the first six months after their first inoculation."
China's first Ad5-nCoV COVID-19 vaccine was rolled out on Friday. One
of the developers of the single-dose vaccine said that the annual
production capacity can reach 500 million doses, which means 500 million
people can be vaccinated in a year.
of the developers of the single-dose vaccine said that the annual
production capacity can reach 500 million doses, which means 500 million
people can be vaccinated in a year.
Phase-I clinical trials of
the vaccine started on March 16, 2020, making it the world's first
COVID-19 candidate vaccine that entered clinical trials.
the vaccine started on March 16, 2020, making it the world's first
COVID-19 candidate vaccine that entered clinical trials.
The
Ad5-nCoV vaccine is a recombinant adenovirus vector vaccine jointly
developed by CanSino Biologics and researchers from the Institute of
Military Medicine under the Academy of Military Sciences led by Chen
Wei.
Ad5-nCoV vaccine is a recombinant adenovirus vector vaccine jointly
developed by CanSino Biologics and researchers from the Institute of
Military Medicine under the Academy of Military Sciences led by Chen
Wei.
Chen is an infectious disease expert and a researcher at the
Institute of Military Medicine under the Academy of Military Sciences.
Institute of Military Medicine under the Academy of Military Sciences.
Unlike
inactivated vaccines, Ad5-nCoV is effective with a single dose and can
bring dual protection ̶ humoral and cellular immunity ̶ at the same
time.
inactivated vaccines, Ad5-nCoV is effective with a single dose and can
bring dual protection ̶ humoral and cellular immunity ̶ at the same
time.
It is the only single-dose COVID-19 vaccine that has been
given a conditional approval to be rolled out in China, state
broadcaster China Central Television (CCTV) reported on Friday.
given a conditional approval to be rolled out in China, state
broadcaster China Central Television (CCTV) reported on Friday.
People can get desirable protective effect after 14 days of inoculation.
The
protective effect can last at least six months after a single-dose
inoculation and it can increase immune response by 10 to 20 times if the
second dose is taken half a year after the first one, Chen told CCTV in
an exclusive interview on Friday.
protective effect can last at least six months after a single-dose
inoculation and it can increase immune response by 10 to 20 times if the
second dose is taken half a year after the first one, Chen told CCTV in
an exclusive interview on Friday.
"We have data for six months so
far to prove the vaccine's efficacy People don't need to take another
dose within the first six months after their first inoculation. What if
the epidemic is not over after six months? We have also developed the
vaccine so that its effect is strengthened even after six months," Chen
said.
far to prove the vaccine's efficacy People don't need to take another
dose within the first six months after their first inoculation. What if
the epidemic is not over after six months? We have also developed the
vaccine so that its effect is strengthened even after six months," Chen
said.
According to data, Chen and other researchers predicted that the vaccine's effect can last two years after two doses.
The most important feature of the vaccine is that it can be produced fast and on a large scale, Chen said.
The
vaccine showed full protection against severe-illness morbidity in
Pakistan, Chen said, noting that it can achieve more than 90 percent
protection against severe-illness.
vaccine showed full protection against severe-illness morbidity in
Pakistan, Chen said, noting that it can achieve more than 90 percent
protection against severe-illness.
The vaccine showed 90.98
percent efficacy rate in preventing severe diseases in its interim
analysis. And it's effective in preventing 65.7 percent of symptomatic
diseases in clinical trials conducted in multiple countries including
Pakistan, Faisal Sultan, special assistant to the Pakistani Minister on
Health, announced in early February.
percent efficacy rate in preventing severe diseases in its interim
analysis. And it's effective in preventing 65.7 percent of symptomatic
diseases in clinical trials conducted in multiple countries including
Pakistan, Faisal Sultan, special assistant to the Pakistani Minister on
Health, announced in early February.
Chen said no serious adverse
reactions associated with the vaccine have been reported in the
vaccinated population so far, including those in extreme environments.
And no specific adverse events have been reported that are different
from those of other vaccines.
reactions associated with the vaccine have been reported in the
vaccinated population so far, including those in extreme environments.
And no specific adverse events have been reported that are different
from those of other vaccines.
The Ad5-nCoV vaccine is actually
mature and reliable. The vaccine with such technology has already been
used for Ebola virus in 2014, Chen said.
mature and reliable. The vaccine with such technology has already been
used for Ebola virus in 2014, Chen said.
People aged under 18 and
over 60 are not allowed to take the other approved vaccines without
conditional approval. However, the Ad5-nCoV vaccine is different.
over 60 are not allowed to take the other approved vaccines without
conditional approval. However, the Ad5-nCoV vaccine is different.
Ad5-nCoV's
Phase-II and Phase-III trials all involved elder participants as people
aged over 55 or 60 have a higher morbidity of severe illness, Chen
said.
Phase-II and Phase-III trials all involved elder participants as people
aged over 55 or 60 have a higher morbidity of severe illness, Chen
said.
The oldest volunteer was a man surnamed Xiong whose antibody
tested positive after the clinical trial results were revealed, this
gave researchers great confidence, Chen noted. She also said they have
safety data of clinical trials for people aged 6-18 which are being
reviewed by China's National Medical Products Administration.
tested positive after the clinical trial results were revealed, this
gave researchers great confidence, Chen noted. She also said they have
safety data of clinical trials for people aged 6-18 which are being
reviewed by China's National Medical Products Administration.
A
PhD volunteer took the vaccine on February 29, 2020, the same day as
Chen. And she had given birth to a baby one week earlier. "She and her
baby are healthy now," Chen said.
PhD volunteer took the vaccine on February 29, 2020, the same day as
Chen. And she had given birth to a baby one week earlier. "She and her
baby are healthy now," Chen said.
Since the vaccine can be
transported and stored at 2C-8C, Chen hopes that the vaccine won't
require cold-chain logistics. She also said they have finished the
clinical trials around the world and will soon release the results.
transported and stored at 2C-8C, Chen hopes that the vaccine won't
require cold-chain logistics. She also said they have finished the
clinical trials around the world and will soon release the results.
In
China there are two types of COVID-19 vaccines ̶ inactivated and
Ad5-nCoV vaccines. When asked which one people should choose, Chen said
those who want to take fewer doses and get faster immune response should
choose the Ad5-nCoV.
China there are two types of COVID-19 vaccines ̶ inactivated and
Ad5-nCoV vaccines. When asked which one people should choose, Chen said
those who want to take fewer doses and get faster immune response should
choose the Ad5-nCoV.
As other variants of the virus have been
found in other parts of the world, Chen said they will follow the safety
of the vaccine over the long term after the rollout, and they will also
track its effectiveness against the new variants. She also stated that
they have started to develop a vaccine against the new variants.
found in other parts of the world, Chen said they will follow the safety
of the vaccine over the long term after the rollout, and they will also
track its effectiveness against the new variants. She also stated that
they have started to develop a vaccine against the new variants.
Expat Hub: Essential information for Expats in China.
20,000+ 外國朋友, 海龜都在關注
關鍵詞
COVID-19
of the
the vaccine
clinical trials
vaccine is
